Department of Radiation Physics, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
J Nucl Med. 2010 Oct;51(10):1616-23. doi: 10.2967/jnumed.110.077578. Epub 2010 Sep 16.
Bioconjugates used in internal radiotherapy exhibit heterogeneous distributions in organs and tumors, implying a risk of nonuniform dose distribution in therapeutic applications using α-particle emitters. Tools are required that provide data on the activity distribution for estimation of absorbed dose on a suborgan level. The α-camera is a quantitative imaging technique developed to detect α-particles in tissues ex vivo. The aim of this study was to evaluate the characteristics of this imaging system and to exemplify its potential use in the development of α-radioimmunotherapy.
The α-camera combines autoradiography with a scintillating technique and optical registration by a charge-coupled device (CCD). The imaging system characteristics were evaluated by measurements of linearity, uniformity, and spatial resolution. The technique was applied for quantitative imaging of (211)At activity distribution in cryosections of tumors, kidney, and whole body. Intratumoral activity distributions of tumor-specific (211)At-MX35-F(ab')(2) were studied at various times after injection. The postinjection activity distributions in the renal cortex and whole kidneys were compared for (211)At-F(ab')(2) and (211)At-IgG trastuzumab.
Quantitative analysis of α-camera images demonstrated that the pixel intensity increased linearly with activity in the imaged specimen. The spatial resolution was 35 ± 11 μm (mean ± SD) and the uniformity better than 2%. Kidney cryosections revealed a higher cortex-to-whole kidney ratio for (211)At-F(ab')(2) than for (211)At-IgG (1.38 ± 0.03 and 0.77 ± 0.04, respectively) at 2 h after injection. Nonuniform intratumoral activity distributions were found for tumor-specific (211)At-MX35-F(ab')(2) at 10 min and 7 h after injection; after 21 h, the distribution was more uniform.
The characteristics of the α-camera are promising, suggesting that this bioimaging system can assist the development, evaluation, and refinement of future targeted radiotherapy approaches using α-emitters. The α-camera provides quantitative data on the activity distribution in tissues on a near-cellular scale and can therefore be used for small-scale dosimetry, improving the prediction of biologic outcomes with α-particles with short path length and high linear energy transfer.
本研究旨在评估该成像系统的特性,并举例说明其在开发α放射性免疫治疗中的潜在应用。
α 相机将放射自显影与闪烁技术和电荷耦合器件(CCD)的光学记录相结合。通过测量线性度、均匀性和空间分辨率来评估成像系统的特性。该技术用于定量成像冷冻切片中肿瘤、肾脏和全身的(211)At 活性分布。研究了注射后不同时间肿瘤特异性(211)At-MX35-F(ab')(2)的肿瘤内活性分布。比较了注射后 2 小时(211)At-F(ab')(2)和(211)At-IgG 曲妥珠单抗在肾皮质和整个肾脏中的活性分布。
α 相机图像的定量分析表明,像素强度与成像标本中的活性呈线性增加。空间分辨率为 35 ± 11 μm(平均值 ± 标准差),均匀性优于 2%。与(211)At-IgG 相比,注射后 2 小时,肾脏冷冻切片中(211)At-F(ab')(2)的皮质与整个肾脏的比值更高(分别为 1.38 ± 0.03 和 0.77 ± 0.04)。在注射后 10 分钟和 7 小时发现肿瘤特异性(211)At-MX35-F(ab')(2)的非均匀肿瘤内活性分布;21 小时后,分布更加均匀。
α 相机的特性很有前途,这表明该生物成像系统可以辅助开发、评估和改进未来使用α 发射器的靶向放射治疗方法。α 相机可提供近细胞尺度组织中活性分布的定量数据,因此可用于小规模剂量测定,提高具有短径和高线性能量转移的α 粒子生物效应预测的准确性。